Vaginal mucosal irritation testing is an essential biocompatibility study for medical devices, materials, and topical products that contact vaginal tissue during clinical use. Performed in accordance with ISO 10993-10, ISO 10993-23 and the equivalent GB/T 16886 series of standards, the evaluation determines whether a test article or its extracts induce erythema, edema, or epithelial injury at the site of mucosal contact. This article explains the applicable standards, sample requirements, test items, methodologies, and frequently asked questions to help manufacturers build compliant biological evaluation dossiers.
Technical Overview
Vaginal mucosal irritation testing is a localized biological safety study designed to determine whether a medical device, biomaterial, or its extracts provoke an irritant response following contact with vaginal mucosa. The study sits within the biological evaluation framework of ISO 10993-1 and is specifically governed by ISO 10993-10 (Tests for irritation and skin sensitization) and ISO 10993-23 (Tests for irritation), together with the Chinese national equivalents GB/T 16886.10 and GB/T 16886.23. Under the ISO 10993-1 contact categorization matrix, irritation data are a core endpoint for any device contacting mucosal membranes, regardless of whether the contact is classified as limited (up to 24 hours), prolonged (24 hours to 30 days), or long-term (exceeding 30 days).
The biological endpoint of interest is a local inflammatory reaction at the mucosal surface, characterized macroscopically by erythema, edema, and abnormal discharge, and microscopically by epithelial degeneration, ulceration, leukocyte infiltration, and vascular congestion. Because vaginal epithelium is structurally thinner and more permeable than skin, skin irritation data cannot be directly extrapolated to mucosal contact, and dedicated mucosal assessment is generally expected by regulators.
Historically, the intravaginal test in the rabbit has served as the reference in vivo method. With the publication of ISO 10993-23:2021, validated in vitro methods based on reconstructed human vaginal epithelium (RhVE) tissues are now formally recognized for certain product categories, in line with the 3Rs principle of replacing, reducing, and refining animal use. Many accredited third-party laboratories now offer both in vivo and in vitro strategies, and the choice depends on the target market, product claims, and the acceptability criteria of the responsible regulatory authority.
Testing Samples
Devices Designed for Direct Vaginal Contact
- Vaginal rings, including contraceptive and hormone-releasing drug-device combination systems
- Vaginal pessaries and support devices for pelvic organ prolapse
- Vaginal dilators and post-surgical rehabilitation devices
- Tampons, menstrual cups, and other intravaginal hygiene products
- Vaginal speculums, retractors, and examination instruments
- Intrauterine devices and systems contacting reproductive tract mucosa
Topical and Drug-Device Combination Products
- Contraceptive gels, foams, films, and spermicidal formulations
- Vaginal moisturizers, lubricants, and personal care gels
- Antimicrobial, antifungal, or hormone-releasing suppositories, tablets, and inserts
- Bioadhesive films, microbicide delivery systems, and in situ gelling formulations
Devices with Indirect or Transient Mucosal Contact
- Urinary catheters and drainage devices, where the vaginal mucosal model is sometimes used as a surrogate for urethral tolerance studies
- Gynecological endoscopes, ultrasound probes, and their protective covers or sheaths
- Surgical meshes, scaffolds, and bioresorbable materials for pelvic floor repair
- Cytology brushes, sampling swabs, and diagnostic collection devices
Materials and Extract Preparation
Raw materials, cured polymers, silicone elastomers, hydrogels, coatings, adhesives, colorants, lubricants, and sterilization process residues can all be evaluated. Test articles are typically prepared as extracts in accordance with ISO 10993-12 using a polar vehicle (such as sodium chloride injection, saline, or cell culture medium) and a non-polar vehicle (such as vegetable oil). Standard extraction ratios include 0.2 g/mL on a mass basis, 3 cm²/mL on a surface area basis, or 6 cm²/mL for elastomers and irregular porous solids. Common extraction conditions are 37 °C for 72 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 2 hours, with the selection justified so that the material is not degraded or altered during extraction.
Testing Items
A typical vaginal mucosal irritation evaluation package includes the following items:
- In vivo intravaginal irritation test in the rabbit, including macroscopic scoring of the mucosal response
- Histopathological examination of excised vaginal tissue
- In vitro irritation testing on reconstructed human vaginal epithelium models as an animal-free alternative
- Calculation of mucosal reaction scores and irritation indices for test, blank, and control groups
- Assessment of clinical observations, including discharge, swelling, and behavioral signs during the in-life phase
- Integrated interpretation of macroscopic, clinical, and microscopic findings against acceptance criteria
Testing Methods
Study Design and Grouping
The reference in vivo model is the healthy adult female rabbit, randomized into treatment groups, commonly with at least three animals per group. Standard groups include the polar test extract, the non-polar test extract where applicable, the corresponding blank extraction vehicle controls, and, when required for method qualification, a positive control using a known mild irritant. Group sizes and exposure regimens are designed to mirror the intended clinical contact duration, distinguishing single-exposure from repeated-exposure study designs.
In Vivo Intravaginal Test Procedure
A fixed volume of test extract, typically one milliliter in the rabbit, is instilled gently into the vaginal canal using a soft applicator or catheter, and brief retention is ensured. For single-exposure designs, animals are observed approximately 24 hours after dosing; for repeated-exposure designs, daily administration continues over a period consistent with the intended use of the device. Throughout the study, general health, behavior, vaginal discharge, and local reactions are recorded. At the scheduled endpoint, animals are humanely euthanized, the vaginal tissue is examined macroscopically, and representative sections are fixed for histopathological processing.
Macroscopic Scoring and Irritation Index
Irritant responses are graded using the standardized ordinal scales of ISO 10993-10 and GB/T 16886.10, in which erythema and eschar formation and edema are each scored from 0 to 4, with discharge and other visible changes documented. Per-animal mucosal reaction scores are calculated as the sum of the grading categories, and group mean scores are compared between the test article and the blank control. A test article is generally considered to have irritant potential when the mean mucosal reaction score exceeds that of the control by a predefined margin, typically one point or more, corroborated by histopathological findings. For context, cumulative irritation indices in the range of 0 to 0.4 are commonly classified as negligible, 0.5 to 1.9 as slight, 2 to 4.9 as moderate, and 5 to 8 as severe.
Histopathological Evaluation
Fixed vaginal specimens are sectioned and stained with hematoxylin and eosin for microscopic examination. The pathologist grades epithelial integrity, the presence of ulceration or erosion, inflammatory cell infiltration, vascular congestion, and tissue edema. Histopathology strengthens the scientific weight of the conclusion, distinguishes chemical irritation from mechanical trauma caused by device geometry, and is frequently requested by regulators when macroscopic findings are ambiguous or when the device is intended for long-term mucosal contact.
In Vitro Alternative Methods
Under ISO 10993-23 and GB/T 16886.23, irritation can be evaluated using three-dimensional reconstructed human vaginal epithelial tissue models cultured on permeable supports. Neat products or test extracts are applied topically to the tissue surface for defined exposure periods, and tissue viability is quantified by MTT reduction. Results may be expressed as viability relative to negative controls treated with buffered saline, or as an ET50 value representing the exposure time that reduces viability to fifty percent, with classification against established irritancy thresholds. A known irritant surfactant serves as the positive control, and blank extraction vehicles are tested in parallel to confirm extraction-system neutrality.
Interpretation and Reporting
The final report issued by accredited third-party laboratories documents the test article description, extraction rationale and conditions, animal or tissue model details, scoring tables, histopathology findings, any protocol deviations, and an integrated conclusion on irritant classification. The results feed directly into the biological evaluation report required for registration, where they are considered alongside cytotoxicity, sensitization, and chemical characterization data in an overall risk assessment.
Applications
Vaginal mucosal irritation testing supports manufacturers across the full product lifecycle:
- Regulatory registration submissions, including device registration dossiers in China, premarket notifications and approvals in the United States, and technical documentation for CE marking under the European framework
- Design verification and material screening during research and development, enabling early elimination of irritant candidates
- Change control evaluation following modifications to materials, suppliers, manufacturing processes, or sterilization methods
- Support of chemical characterization and toxicological risk assessment activities under ISO 10993-18 and ISO 10993-17
- Gap closure in biological evaluation reports where existing literature data are insufficient for mucosal contact claims
- Safety dossiers for drug-device combination products and intravaginal delivery systems
FAQ
Which standards govern vaginal mucosal irritation testing?
The primary standards are ISO 10993-10 and ISO 10993-23 at the international level, with GB/T 16886.10 and GB/T 16886.23 as the corresponding Chinese national standards. Sample extraction is governed by ISO 10993-12 or GB/T 16886.12.
When is this test required for a medical device?
The test is expected whenever a device or its released materials contact vaginal or reproductive tract mucosa, for any contact duration. It can be waived only when existing data on identical materials, formulations, and exposure conditions provide adequate justification documented in the biological evaluation.
Can in vitro testing replace the animal study?
ISO 10993-23 formally recognizes reconstructed human epithelium methods for irritation assessment, and in vitro approaches are increasingly accepted for certain extract-based and topical evaluations. However, acceptance varies by regulatory authority, product type, and claim structure, so the strategy should be confirmed with accredited third-party laboratories and the target market requirements before study initiation.
What sample quantity is needed for testing?
The required quantity depends on the device geometry and extraction ratio. As a general rule, sufficient material should be supplied to prepare both polar and non-polar extracts at 3 cm²/mL or 6 cm²/mL on a surface area basis, or 0.2 g/mL on a mass basis, with additional material reserved for control characterization.
Which animal model is used for the in vivo study?
The healthy adult female rabbit is the preferred and most widely accepted model for intravaginal irritation testing, although rodent models may be used in specific study designs. The selected species and strain are documented in the study protocol.
How long does the evaluation take?
Typical timelines include extraction for up to 72 hours, an acclimation period for the animals, an in-life phase ranging from one day for single-exposure designs to about one week for repeated-exposure designs, followed by histopathological processing and reporting. Overall, manufacturers should generally plan for approximately three to six weeks from sample receipt to the final report.